Comprehensive Profiling of Approved Anti-CD20 mAbs Using Fc Effector Function Platform
May 12, 2025
Authors: P. Hsueh, M. Friedman, S. Jatiani (2024)
Application Note
Summary: This study uses SeromYx’s Fc effector function platform to profile rituximab, ofatumumab, and obinutuzumab, the first three approved anti-CD20 monoclonal antibodies. By comparing their biophysical binding and immune cell effector functions, the analysis provides insights to optimize current therapies and guide next-generation antibody development.
The World Vaccine Congress Europe 2025
Festival of Biologics
The Fc-Mediated Effector Function Summit
Authors: Atyeo et al. Immunity (2020)
Authors: Kaplonek P, et al. Sci Transl Med. 2022 May 18;14(645):eabm2311.
Authors: Hawman, David W. et al. eBioMedicine, Volume 115, 105698
